Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 7/20 | 0.39 |
| ▸ | APAF1 | O14727 | 4/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774055 | 0.82 | MAPT (0.43) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2787353 | 0.82 | CNR1 (0.46) | MAPTALDH1A1GAASMN1; SMN2HTT | |
| SCHEMBL2773055 | 0.81 | SENP6 (0.49) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2773951 | 0.81 | CNR1 (0.45) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2791335 | 0.81 | MAPT (0.44) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2788290 | 0.80 | MAPT (0.39) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL3475816 | 0.80 | HRH4 (0.46) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2772654 | 0.79 | KMT2A (0.41) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2775659 | 0.78 | MAPT (0.39) | MAPTALDH1A1GAAAPAF1SENP7 | |
| SCHEMBL2772122 | 0.78 | HPGD (0.44) | MAPTALDH1A1GAAAPAF1SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | claimed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | claimed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | MAPT 4555/4885ALDH1A1 2179/4885GAA 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.